CN101065377B - 咪唑并[1,2-a]吡啶化合物、组合物、与其有关的应用和方法 - Google Patents

咪唑并[1,2-a]吡啶化合物、组合物、与其有关的应用和方法 Download PDF

Info

Publication number
CN101065377B
CN101065377B CN2005800386913A CN200580038691A CN101065377B CN 101065377 B CN101065377 B CN 101065377B CN 2005800386913 A CN2005800386913 A CN 2005800386913A CN 200580038691 A CN200580038691 A CN 200580038691A CN 101065377 B CN101065377 B CN 101065377B
Authority
CN
China
Prior art keywords
methyl
imidazo
tolyl
pyridin
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800386913A
Other languages
English (en)
Chinese (zh)
Other versions
CN101065377A (zh
Inventor
J·L·法尔科
A·帕洛莫
A·古格莱塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrer Internacional SA
Original Assignee
Ferrer Internacional SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Internacional SA filed Critical Ferrer Internacional SA
Publication of CN101065377A publication Critical patent/CN101065377A/zh
Application granted granted Critical
Publication of CN101065377B publication Critical patent/CN101065377B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2005800386913A 2004-11-11 2005-11-04 咪唑并[1,2-a]吡啶化合物、组合物、与其有关的应用和方法 Expired - Fee Related CN101065377B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04105698.7 2004-11-11
EP04105698 2004-11-11
PCT/EP2005/055753 WO2006051063A1 (en) 2004-11-11 2005-11-04 Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto

Publications (2)

Publication Number Publication Date
CN101065377A CN101065377A (zh) 2007-10-31
CN101065377B true CN101065377B (zh) 2011-07-27

Family

ID=34929843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800386913A Expired - Fee Related CN101065377B (zh) 2004-11-11 2005-11-04 咪唑并[1,2-a]吡啶化合物、组合物、与其有关的应用和方法

Country Status (24)

Country Link
US (1) US20080200473A1 (https=)
EP (1) EP1814880B1 (https=)
JP (1) JP2008519805A (https=)
KR (1) KR20070084026A (https=)
CN (1) CN101065377B (https=)
AR (1) AR051626A1 (https=)
AT (1) ATE421962T1 (https=)
AU (1) AU2005303811A1 (https=)
BR (1) BRPI0517796A (https=)
CA (1) CA2585315A1 (https=)
DE (1) DE602005012598D1 (https=)
DK (1) DK1814880T3 (https=)
ES (1) ES2321858T3 (https=)
IL (1) IL182963A0 (https=)
MX (1) MX2007005611A (https=)
NO (1) NO20072831L (https=)
PA (1) PA8652101A1 (https=)
PE (1) PE20060967A1 (https=)
PL (1) PL1814880T3 (https=)
PT (1) PT1814880E (https=)
RU (1) RU2007121864A (https=)
TW (1) TWI357412B (https=)
UY (1) UY29204A1 (https=)
WO (1) WO2006051063A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
MX2008014796A (es) * 2006-05-31 2008-12-02 Hoffmann La Roche Derivados de aril-4-etinil-isoxazol.
AU2007288124B2 (en) * 2006-08-24 2013-04-04 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
AU2009239430B2 (en) 2008-04-21 2015-01-22 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
CA2724842A1 (en) 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
WO2010045615A2 (en) 2008-10-16 2010-04-22 Cenomed Biosciences, Llc Treatment of organophosphate exposure with ocinaplon
EP2376490B1 (en) * 2008-12-04 2013-01-23 Proximagen Limited Imidazopyridine compounds
EP2496578A4 (en) 2009-11-05 2013-08-21 Univ Notre Dame Du Lac IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF
WO2012036278A1 (ja) * 2010-09-17 2012-03-22 大正製薬株式会社 グリシントランスポーター阻害物質
CN108348510B (zh) 2015-09-17 2022-01-04 圣母大学 针对分枝杆菌感染有用的含有苄胺的杂环化合物以及组合物
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
CN106906486B (zh) * 2017-02-22 2018-12-11 华南理工大学 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
AU2021213811A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
KR20260004434A (ko) * 2023-04-24 2026-01-08 상하이 에스아이엠알 바이오테크놀로지 컴퍼니 리미티드 이미다조피리딘 또는 이미다조피라진 화합물, 이의 제조 방법, 약학 조성물 및 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767755A (en) * 1986-02-05 1988-08-30 Synthelabo 3-(acylaminomethyl)imidazo[1,2-a]pyridine derivatives and pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
ES2032455T3 (es) * 1986-01-22 1993-02-16 Synthelabo Procedimiento para preparar derivados de 3-acilaminometil-imidazo (-1,2-a)piridinas.
FR2593181B1 (fr) * 1986-01-22 1988-04-01 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US20040204443A1 (en) * 2003-01-27 2004-10-14 Arthur Zaks Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767755A (en) * 1986-02-05 1988-08-30 Synthelabo 3-(acylaminomethyl)imidazo[1,2-a]pyridine derivatives and pharmaceutical compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Schmitt M.Imidazo[1,2-b]pyridazines. XXIII Some 5-DeazaAnalogues.Syntheses of Some 2-Aryl-6-(choro, methoxyorunsubstituted)-3-(variously substituted)Imidazo[1,2-a]pyridinesand Their Affinity for Central andMitochondrialBenzodiazepine Receotors.Australian J. Of Chemistry, XX, XX50 7.1997,50(7),719-725. *
SchmittM.Imidazo[1 2-b]pyridazines. XXIII Some 5-DeazaAnalogues.Syntheses of Some 2-Aryl-6-(choro

Also Published As

Publication number Publication date
TWI357412B (en) 2012-02-01
UY29204A1 (es) 2006-01-31
PA8652101A1 (es) 2006-10-13
NO20072831L (no) 2007-08-01
US20080200473A1 (en) 2008-08-21
TW200624432A (en) 2006-07-16
RU2007121864A (ru) 2008-12-20
ATE421962T1 (de) 2009-02-15
JP2008519805A (ja) 2008-06-12
EP1814880A1 (en) 2007-08-08
CA2585315A1 (en) 2006-05-18
DK1814880T3 (da) 2009-05-18
PL1814880T3 (pl) 2009-07-31
CN101065377A (zh) 2007-10-31
AU2005303811A1 (en) 2006-05-18
EP1814880B1 (en) 2009-01-28
AR051626A1 (es) 2007-01-24
ES2321858T3 (es) 2009-06-12
IL182963A0 (en) 2007-08-19
WO2006051063A1 (en) 2006-05-18
PT1814880E (pt) 2009-04-23
PE20060967A1 (es) 2006-09-20
DE602005012598D1 (de) 2009-03-19
KR20070084026A (ko) 2007-08-24
BRPI0517796A (pt) 2008-10-28
MX2007005611A (es) 2007-07-11

Similar Documents

Publication Publication Date Title
CN101065377B (zh) 咪唑并[1,2-a]吡啶化合物、组合物、与其有关的应用和方法
KR101058292B1 (ko) Ｐ38 억제제로 유용한 니코틴아미드 유도체
JP5733982B2 (ja) サイトカインの産生を抑制する化合物及びその調製方法
DE60314639T2 (de) Fusionierte heteroaryl-derivate zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
JP5582634B2 (ja) ４−置換フェノキシフェニル酢酸誘導体
TWI491595B (zh) 作為香草類化合物受體之配體之經取代苯基尿素及苯基醯胺
JP5265541B2 (ja) Ｎ−（アミノヘテロアリール）−１ｈ−インドール−２−カルボキサミド誘導体、その調製およびその治療における使用
JP2002513387A (ja) 選択的β▲下３▼アドレナリン作動性アゴニスト
TWI344956B (en) Caspase inhibitors and uses thereof
TWI333950B (en) New benzimidazole derivatives
TWI403512B (zh) 咪唑并〔１，２-ｂ〕嗒類、製法、用途、中間物及組成物
TW200904425A (en) Organic compounds
ES2282857T3 (es) Derivados de bifenilcarboxamida y su uso como inhibidores de quinasa p38.
ZA200606530B (en) (3-Oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
CN113831301A (zh) 苯并噻唑类衍生物及其用途
JPS59141564A (ja) 新規ピリダジン誘導体，その製造方法及び該誘導体を含有する神経系治療剤
JP5823543B2 (ja) 新規オキサゾロン及びピロリジノン置換アリールアミド
JP2008500944A (ja) ２−置換フェニル−５，７−ジアルキル−３，７−ジヒドロピロロ［２，３−ｄ］ピリミジン−４−オン誘導体、その製法およびその医薬用途
EP1334100A1 (en) Bombesin receptor antagonists
CN114456150A (zh) Nr2b受体拮抗剂或其可药用的盐、制备方法及用途
CN108697697A (zh) 治疗及/或预防纤维性疾病的胺基萘醌化合物
EP1334102A1 (en) Bombesin receptor antagonists
US20140303186A1 (en) Nitrogen-containing fused ring compounds as crth2 antagonists
JP2004515491A (ja) 縮合ピロールカルボキサミド類の合成
WO2019232663A1 (zh) 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110727

Termination date: 20121104